Serum Copeptin Levels Predict Clinical Outcomes After Successful Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction

다국어 초록 (Multilingual Abstract)

Background: Serum copeptin has been demonstrated to be useful in early risk stratification and prognostication of patients with acute myocardial infarction (AMI). However, the prognostic value of copeptin after percutaneous coronary intervention (PCI) for clinical outcomes remains uncertain. We investigated the prognostic role of serum copeptin levels immediately after successful PCI as a prognostic marker for major adverse cardiac events (MACE; comprising death, repeat PCI, recurrent MI, or coronary artery bypass grafting) in patients with AMI.
Methods: A retrospective study was performed in 149 patients with AMI who successfully received PCI. Serum copeptin levels were analyzed in blood samples collected immediately after PCI. The association between copeptin levels and MACE during the follow-up period was evaluated.
Results: MACE occurred in 34 (22.8%) patients during a median follow-up of 30.1 months. MACE patients had higher copeptin levels than non-MACE patients did. Multiple logistic regression analysis showed that the increase in serum copeptin levels was associated with increased MACE incidence (odds ratio=1.6, P=0.005).
Conclusions: A high level of serum copeptin measured immediately after PCI was associated with MACE in patients with AMI during long-term follow-up. Serum copeptin levels can serve as a prognostic marker in patients with AMI after successful PCI.

참고문헌 (Reference)

1 Jarai R, "Usefulness of pre-operative copeptin concentrations to predict post-operative outcome after major vascular surgery" 108 : 1188-1195, 2011

2 Thygesen K, "Third universal definition of myocardial infarction" 60 : 1581-1598, 2012

3 Slagman A, "Temporal release pattern of copeptin and troponin T in patients with suspected acute coronary syndrome and spontaneous acute myocardial infarction" 61 : 1273-1282, 2015

4 Katan M, "Stress hormones predict cerebrovascular re-events after transient ischemic attacks" 76 : 563-566, 2011

5 Tu WJ, "Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke" 25 : 771-778, 2013

6 Jang JS, "Prognostic value of creatine kinase-myocardial band isoenzyme elevation following percutaneous coronary intervention: a meta-analysis" 81 : 959-967, 2013

7 CLSI, "Procedures for the Handling and Processing of Blood Specimen for Common Laboratory Tests; H18-A4"

8 Land H, "Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor" 295 : 299-303, 1982

9 Ioannidis JP, "Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention" 42 : 1406-1411, 2003

10 Akkerhuis KM, "Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?" 105 : 554-556, 2002

11 Myler RK, "Lesion morphology and coronary angioplasty: current experience and analysis" 19 : 1641-1652, 1992

12 Geri G, "Is copeptin level associated with 1-year mortality after out-of-hospital cardiac arrest? Insights from the Paris registry" 43 : 422-429, 2015

13 Reichlin T, "Incremental value of copeptin for rapid rule out of acute myocardial infarction" 54 : 60-68, 2009

14 Ibáñez B, "Evolving therapies for myocardial ischemia/reperfusion injury" 65 : 1454-1471, 2015

15 Manginas A, "Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method" 83 : 1562-1565, 1999

16 Zellweger MJ, "Coronary artery disease progression late after successful stent implantation" 59 : 793-799, 2012

17 Morgenthaler NG, "Copeptin: clinical use of a new biomarker" 19 : 43-49, 2008

18 Katan M, "Copeptin: a novel, independent prognostic marker in patients with ischemic stroke" 66 : 799-808, 2009

19 Tasevska I, "Copeptin predicts coronary artery disease cardiovascular and total mortality" 102 : 127-132, 2016

20 von Haehling S, "Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease" 162 : 27-32, 2012

21 Bolignano D, "Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology" 52 : 1447-1456, 2014

22 McMurray JJ, "Clinical practice. Systolic heart failure" 362 : 228-238, 2010

23 Cutlip DE, "Clinical end points in coronary stent trials: a case for standardized definitions" 115 : 2344-2351, 2007

24 Kelly D, "C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction" 14 : 739-745, 2008

25 Khan SQ, "C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study" 115 : 2103-2110, 2007

26 Morgenthaler NG, "Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin" 52 : 112-119, 2006

27 Stone GW, "A prospective natural-history study of coronary atherosclerosis" 364 : 226-235, 2011

28 Ibanez B, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)" 39 : 119-177, 2018

29 Voors AA, "-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study" 30 : 1187-1194, 2009